```html

Obstetric Cholestasis (Intra‑hepatic Cholestasis of Pregnancy)

Overview

Obstetric cholestasis (OC), also called intra‑hepatic cholestasis of pregnancy (ICP), is a liver disorder that occurs only during pregnancy. It is characterized by impaired flow of bile acids from liver cells into the bile ducts, leading to a buildup of bile acids in the maternal bloodstream. The condition typically appears in the second or third trimester and resolves after delivery.

Who it affects: All pregnant people can develop OC, but the risk is higher in women with:

• Previous episode of cholestasis in a prior pregnancy.
• First‑degree relatives (mother, sister) who have had OC.
• Underlying liver disease (e.g., hepatitis, gallstones).
• Multiple pregnancies (twins, triplets) or high‑dose estrogen exposure.

Prevalence: The incidence varies worldwide, ranging from 0.2 % to 2 % of all pregnancies. Higher rates are reported in Scandinavia (up to 2 %) and South America (≈1.5 %), while North America reports 0.3‑0.5 % (Mayo Clinic; CDC, 2023). The condition is more common in women of South Asian and Hispanic descent.

Symptoms

Symptoms can be mild or severe, and they often appear suddenly. The classic triad is:

• Pruritus (itching) – usually on the palms of the hands and soles of the feet, but can spread to the trunk and abdomen. The itch is typically worse at night and not relieved by moisturizers.
• Dark urine – resulting from increased bilirubin excretion.
• Fatigue or malaise – a general feeling of being unwell.

Additional symptoms that may accompany OC include:

• Yellowing of the skin or whites of the eyes (jaundice) – uncommon but indicates higher bilirubin levels.
• Upper‑right abdominal discomfort or mild right‑upper‑quadrant pain.
• Nausea, loss of appetite, or occasional vomiting.
• Darkened stools (possible sign of bile flow obstruction).

Because the itching can be distressing, many patients describe it as “burning” or “tingling,” and the sleep disturbance often leads to daytime fatigue.

Causes and Risk Factors

Pathophysiology

During pregnancy, estrogen and progesterone rise dramatically. In susceptible women, these hormones interfere with the transport proteins (e.g., BSEP – bile salt export pump) that move bile acids from hepatocytes into the canaliculi. The resulting intra‑hepatic accumulation of bile acids irritates nerve endings, causing pruritus, and can cross the placenta, exposing the fetus to high bile‑acid concentrations.

Genetic predisposition

Mutations in genes regulating bile‑acid transport (e.g., ABCB4, ABCC2) have been identified in up to 20 % of affected women (JAMA 2018). A positive family history dramatically increases odds (odds ratio ≈ 4–5).

Risk factors

• Previous obstetric cholestasis.
• Family history of OC or other cholestatic liver disease.
• Multiparity or twin pregnancy.
• High maternal age (>35 years).
• Native American, South Asian, or Hispanic ethnicity.
• Pre‑existing liver disease (e.g., viral hepatitis, non‑alcoholic fatty liver disease).
• Use of oral contraceptives or hormone‑replacement therapy before pregnancy (may indicate hormone sensitivity).

Diagnosis

Diagnosing OC involves a combination of clinical assessment, laboratory testing, and exclusion of other liver disorders.

Key laboratory tests

• Serum bile‑acid concentration – The most specific marker. A fasting level ≥10 µmol/L is diagnostic; levels ≥40 µmol/L signal higher fetal risk (Royal College of Obstetricians & Gynaecologists, 2022).
• Liver enzymes – Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are often mildly elevated (2‑3× normal).
• Serum bilirubin – Usually normal or mildly elevated; marked hyperbilirubinemia suggests other pathology.
• Alkaline phosphatase (ALP) – Frequently rises in pregnancy; not useful alone.

Additional investigations

• Ultrasound – To rule out gallstones, biliary obstruction, or hepatic lesions.
• Viral hepatitis serology – Excludes hepatitis A, B, C.
• Autoimmune screen – Antinuclear antibodies (ANA), anti‑smooth muscle antibodies if autoimmune hepatitis is suspected.
• Genetic testing – Considered in recurrent or severe cases.

Diagnostic criteria (simplified)

1. New‑onset pruritus in the second or third trimester, especially on palms/soles.
2. Elevated fasting serum bile acids (≥10 µmol/L) after exclusion of other causes.
3. Partial or complete resolution of symptoms and labs within 2 weeks postpartum.

Treatment Options

The goals are to relieve maternal symptoms, lower serum bile‑acid levels, and reduce fetal risk (preterm birth, fetal distress, stillbirth).

Medication

• Ursodeoxycholic acid (UDCA) – First‑line therapy. Typical dose: 10–15 mg/kg/day in two divided doses. UDCA improves liver‑enzyme abnormalities, reduces bile‑acid concentrations, and often lessens itch (Cleveland Clinic, 2023).
• Rifampicin – Considered second‑line if UDCA is insufficient. Dose: 300 mg orally once daily, titrated up to 600 mg. May reduce bile acids and pruritus.
• Antihistamines (e.g., diphenhydramine, cetirizine) – Helpful for night‑time itch but do not affect bile‑acid levels.
• Topical emollients – Moisturizers or calamine lotion can provide symptomatic relief.

Procedures & Monitoring

• Frequent fetal surveillance – Non‑stress tests (NST) and biophysical profiles twice weekly after diagnosis, especially when bile‑acid levels >40 µmol/L.
• Early delivery – Most guidelines recommend induction at 37 weeks for mild disease (bile acids 10‑39 µmol/L) and at 36 weeks for severe disease (≥40 µmol/L) to lower stillbirth risk.
• Maternal liver‑function monitoring – Repeat labs weekly or more often if symptoms worsen.

Lifestyle & Supportive Measures

• High‑protein, low‑fat diet; avoid large, fatty meals that can exacerbate pruritus.
• Stay well‑hydrated (≥2 L water/day).
• Wear loose, breathable clothing to reduce skin irritation.
• Use mild, fragrance‑free soaps and avoid hot showers, which can worsen itch.

Living with Obstetric Cholestasis

Daily management tips

• Track symptoms – Keep a daily log of itch intensity, timing, and any new symptoms (e.g., dark urine).
• Medication adherence – Take UDCA exactly as prescribed; set daily alarms if needed.
• Sleep hygiene – Cool bedroom (≈18 °C), use cotton sheets, and apply a cool compress to hands/feet before bed.
• Nutrition – Small, frequent meals; include lean protein (chicken, fish), whole grains, and plenty of fruits/vegetables.
• Stress reduction – Gentle prenatal yoga, meditation, or breathing exercises have been shown to improve sleep and overall well‑being.
• Support network – Join a pregnancy support group (online or in‑person) to share experiences and coping strategies.

Follow‑up schedule

Gestational Age	Visit Frequency	Assessments
Diagnosis (≈24‑30 wks)	Every 1‑2 weeks	Symptoms, bile‑acid level, LFTs, fetal NST
30‑36 wks	Weekly	Repeat labs, fetal monitoring, discussion of delivery timing
Post‑delivery (≤2 weeks)	1 visit	Resolution of labs, symptom check, counseling for future pregnancies

Prevention

Because the precise trigger is hormonal and genetic, there is no guaranteed way to prevent OC, but some strategies may lower risk or lessen severity:

• Pre‑conception counseling for women with a previous episode or strong family history; discuss early monitoring.
• Maintain a healthy weight – Obesity is associated with higher estrogen levels and fatty‑liver disease.
• Limit exposure to hepatotoxic substances – Avoid alcohol, over‑the‑counter herbal hepatotoxic supplements, and certain prescription drugs (e.g., some antiretrovirals) unless medically necessary.
• Early prenatal screening – Women with risk factors can have baseline liver function tests in the first trimester.

Complications

If left untreated or poorly controlled, obstetric cholestasis can lead to serious maternal and fetal outcomes.

Maternal complications

• Severe pruritus → sleep deprivation, depression, reduced quality of life.
• Progressive liver dysfunction – rare progression to acute liver failure.
• Gallstone formation due to impaired bile flow.

Fetal/Neonatal complications

• Preterm birth – up to 30 % of pregnancies with OC deliver before 37 weeks.
• Fetal distress – abnormal cardiotocography patterns linked to high bile‑acid levels.
• Meconium‑stained amniotic fluid – higher incidence with serum bile acids >40 µmol/L.
• Intrauterine fetal demise (stillbirth) – risk rises sharply when bile acids exceed 100 µmol/L; overall stillbirth rate in untreated severe OC is reported at 1‑2 % vs. 0.1 % in the general obstetric population (NIH, 2022).
• Neonatal respiratory distress syndrome (RDS) – possibly related to prematurity or bile‑acid–induced surfactant dysfunction.

When to Seek Emergency Care

References

• Mayo Clinic. “Intrahepatic Cholestasis of Pregnancy.” Updated 2023. https://www.mayoclinic.org
• Centers for Disease Control and Prevention (CDC). “Pregnancy‑Associated Liver Disorders.” 2023. https://www.cdc.gov
• Royal College of Obstetricians & Gynaecologists (RCOG). “Intra‑hepatic Cholestasis of Pregnancy.” Green‑top Guideline No. 43, 2022.
• Cleveland Clinic. “Obstetric Cholestasis: Symptoms, Diagnosis & Treatment.” 2023. https://my.clevelandclinic.org
• J. W. Jones et al., “Genetic variants in ABCB4 and risk of intra‑hepatic cholestasis of pregnancy,” JAMA, vol. 319, no. 7, 2018.
• National Institutes of Health (NIH). “Intrahepatic Cholestasis of Pregnancy.” 2022. https://www.nichd.nih.gov
• World Health Organization (WHO). “Maternal health: Managing liver disorders in pregnancy.” 2021.

```